Shares of Neurogene Inc. (NASDAQ:NGNE – Get Free Report) have been given an average rating of “Buy” by the nine research firms that are covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $51.00.
A number of analysts recently weighed in on the stock. Leerink Partnrs restated an “outperform” rating on shares of Neurogene in a report on Monday, April 29th. BMO Capital Markets assumed coverage on Neurogene in a research note on Thursday, June 27th. They set an “outperform” rating and a $65.00 price objective for the company. SVB Leerink started coverage on Neurogene in a research report on Monday, April 29th. They set an “outperform” rating and a $46.00 target price on the stock. HC Wainwright decreased their price target on Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Monday. Finally, Baird R W upgraded Neurogene to a “strong-buy” rating in a report on Tuesday, June 11th.
View Our Latest Stock Report on Neurogene
Neurogene Stock Performance
Neurogene (NASDAQ:NGNE – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The firm had revenue of $0.93 million during the quarter. Sell-side analysts anticipate that Neurogene will post -4.15 EPS for the current year.
Hedge Funds Weigh In On Neurogene
Several institutional investors and hedge funds have recently bought and sold shares of NGNE. Quest Partners LLC acquired a new stake in shares of Neurogene during the second quarter worth approximately $55,000. SG Americas Securities LLC acquired a new stake in shares of Neurogene during the first quarter worth approximately $120,000. Privium Fund Management UK Ltd acquired a new stake in shares of Neurogene during the first quarter worth approximately $274,000. BML Capital Management LLC acquired a new stake in shares of Neurogene during the fourth quarter worth approximately $478,000. Finally, Rhumbline Advisers acquired a new stake in shares of Neurogene during the second quarter worth approximately $491,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.
Neurogene Company Profile
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
- Five stocks we like better than Neurogene
- Find and Profitably Trade Stocks at 52-Week Lows
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Ride Out The Recession With These Dividend Kings
- Jeff Brown’s Exegesis AI Stock Picks
- What is the Australian Securities Exchange (ASX)
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.